TrialQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2021

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN).

Janet Ford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.